Skip to main navigation
  • Newsroom
  • BD & Partnering
  • Get in Touch
  • LinkedIn
Editas Medicine logo
  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors
  • Newsroom
  • BD & Partnering
  • Get in Touch
  • LinkedIn

Media & Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting Materials
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
  • Investor FAQs
  • Contact

Investors

Overview

Stock Quote

Change
Volume
52 Week High
52 Week Low
May 16, 2026 5:56 PM EDT

Minimum 15 minutes delayed. Source: LSEG

Upcoming Events
2026 Jefferies Global Healthcare Conference
Jun 4, 2026 at 4:20 PM EDT
Click here for Webcast
Add to Outlook
Add to Google Calendar
Recent News
May 14, 2026
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
May 5, 2026
Editas Medicine Announces First Quarter 2026 Results and Business Updates
April 27, 2026
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

>> Press Release See All

  • See all

Sign up For E-mail Alerts

Sign Up

For Investors and Media:

Editas Medicine, Inc.
E-mail: ir@editasmed.com

>> Main navigation

  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors

>> Footer menu

  • Get in Touch
  • Investors
  • Privacy Policy
  • Terms of Use
©Copyright 2026 Editas Medicine